Guardant Health Director Sells 100 Shares at $65.84 on 2025-09-02
ByAinvest
Wednesday, Sep 3, 2025 6:56 pm ET1min read
GH--
Guardant Health, Inc. (GH) has announced that Director Joyce Meghan V. sold 100 shares of the company's common stock on September 2, 2025. The shares were sold at a price of $65.84 per share, resulting in an aggregate market value of $6,584.
The transaction was executed through Charles Schwab & Co., Inc. and is part of the company's equity compensation program. The shares were acquired by Director Joyce Meghan V. through restricted stock lapses: 34 shares on June 12, 2025, and 66 shares on July 4, 2025. These shares were listed as part of the company's compensation package [1].
This sale is part of a series of recent insider transactions. In June 2025, Director Joyce Meghan V. sold 100 shares for $4,166 on June 2, 2025, and 3,337 shares for $157,573 on June 13, 2025. The filings disclose these transactions, providing transparency to investors and regulatory bodies [1].
The recent positive performance of Guardant Health's stock, which has seen a 4.82% increase amid promising new growth plans and strategic partnerships, may have influenced the sale. The company has recently formed a partnership with the American Cancer Society to enhance cancer screenings and promote health equity [2]. Additionally, analysts have revised their price targets upward, reflecting the company's robust financial guidance and promising future outlook [2].
Despite the recent insider sales, the overall market sentiment for Guardant Health remains positive. The company's strategic partnerships and financial performance are seen as strong drivers of future growth.
References:
[1] https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-c59cd2c49d75.html
[2] https://stockstotrade.com/news/guardanthealthinc-gh-news-2025_08_30/
Guardant Health, Inc. (GH) announced that Director Joyce Meghan V. has recently sold 100 shares at a price of $65.84 per share on September 2, 2025.
Title: Guardant Health, Inc. Director Joyce Meghan V. Sells 100 Shares on September 2, 2025Guardant Health, Inc. (GH) has announced that Director Joyce Meghan V. sold 100 shares of the company's common stock on September 2, 2025. The shares were sold at a price of $65.84 per share, resulting in an aggregate market value of $6,584.
The transaction was executed through Charles Schwab & Co., Inc. and is part of the company's equity compensation program. The shares were acquired by Director Joyce Meghan V. through restricted stock lapses: 34 shares on June 12, 2025, and 66 shares on July 4, 2025. These shares were listed as part of the company's compensation package [1].
This sale is part of a series of recent insider transactions. In June 2025, Director Joyce Meghan V. sold 100 shares for $4,166 on June 2, 2025, and 3,337 shares for $157,573 on June 13, 2025. The filings disclose these transactions, providing transparency to investors and regulatory bodies [1].
The recent positive performance of Guardant Health's stock, which has seen a 4.82% increase amid promising new growth plans and strategic partnerships, may have influenced the sale. The company has recently formed a partnership with the American Cancer Society to enhance cancer screenings and promote health equity [2]. Additionally, analysts have revised their price targets upward, reflecting the company's robust financial guidance and promising future outlook [2].
Despite the recent insider sales, the overall market sentiment for Guardant Health remains positive. The company's strategic partnerships and financial performance are seen as strong drivers of future growth.
References:
[1] https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-c59cd2c49d75.html
[2] https://stockstotrade.com/news/guardanthealthinc-gh-news-2025_08_30/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet